angiotensin ii has been researched along with candoxatrilat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Connell, JM; Cussans, NJ; Davidson, G; Dilly, SG; Doyle, J; Jardine, AG; Leckie, BL; Lever, AF; Northridge, D | 1 |
| Ferro, CJ; Haynes, WG; Spratt, JC; Webb, DJ | 1 |
2 trial(s) available for angiotensin ii and candoxatrilat
| Article | Year |
|---|---|
The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
Topics: Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Carbamates; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Injections, Intravenous; Kidney; Male; Middle Aged; Natriuresis; Neprilysin; Propionates; Renin; Sodium | 1990 |
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Coronary Vessels; Cross-Over Studies; Cyclohexanecarboxylic Acids; Enalapril; Endothelin-1; Humans; Hypertension; Injections, Intra-Arterial; Male; Middle Aged; Myocardium; Neprilysin; Peptides, Cyclic; Protease Inhibitors; Renin; Single-Blind Method; Thiorphan; Vasoconstriction | 1998 |